TY - JOUR. T1 - Future developments and new research in genitourinary cancers. Perspectives. AU - Alexander, Richard B.. AU - Coffey, Donald S.. PY - 1987/8/1. Y1 - 1987/8/1. N2 - Significant advances in the therapy of genitourinary cancers have occurred, yet the challenge of metastatic disease in many of these tumors remains unsolved. The great success achieved in the treatment of testicular cancer has been in large part due to the development of effective systemic therapy. Effective treatment for metastatic transitional cell carcinoma is just beginning to be described. Advanced renal and prostatic carcinomas remain a major clinical problem with no effective curative therapy. Novel new approaches to systemic therapy developed on sound basic experimental principles are needed. Several potential approaches such as angiogenesis factor, interleukin II, lymphokine activated killer cells, and tumor necrosis factor are discussed.. AB - Significant advances in the therapy of genitourinary cancers have ...
The Claire & John Bertucci Center for Genitourinary Cancers is one of the largest, most experienced centers in New England for the treatment and care of patients with bladder, kidney, prostate and other genitourinary cancers.
The Genitourinary Cancer Genetics and Prevention Program aims to provide a comprehensive, personalized consultation to meet the clinical needs and expectations of each patient. Prior to each visit the team will review available records including clinic notes, detailed family history, radiographic images, and pathology reports. Many patients will meet first with a genetic counselor who will review family history and other risk factors for cancer, explain the role of genetic testing for hereditary cancer syndromes, discuss the limitations and the implications of testing, and provide an overall cancer risk assessment. Patients with cancer or those with increased risk will have the opportunity to consult with a clinician well versed in hereditary forms of genitourinary malignancies. These visits will be to discuss the clinical aspects of their disease, unique aspects of hereditary forms of cancer, and specific diagnostic and treatment aspects based on the results of genetic testing. After the visit, ...
Reports and findings from the American Society of Clinical Oncologys Genitourinary Cancer Symposium, held February 26th though 28th in Orlando, Florida. 
Research on promising new therapies and data on the relative benefits of established treatments for prostate cancer were released today, in advance of the fourth annual Genitourinary Cancers Symposium, being held February 2-4, 2012, at the San Francisco Marriott Marquis in San Francisco, Calif.. The results of five studies were highlighted in a media presscast (press briefing via live webcast):. 1) Vigorous Exercise Linked to Expression of Certain Genes in Early-Stage Prostate Cancer: A study shows that men with early-stage prostate cancer who exercise vigorously at least three hours a week have more than 180 genes that are expressed differently in the prostate than those who did not exercise as intensively. These genes include known tumor suppressor genes and DNA repair pathways, suggesting a number of potential mechanisms by which vigorous exercise may help delay cancer progression, as prior studies have shown.. 2) IMRT Better Than Conformal Radiation Therapy for Reducing Prostate Cancer ...
This video reviews new studies examining the genetic drivers of three rare genitourinary cancers: von Hippel-Lindau disease, advanced papillary renal cell carcinoma, and penile cancer. 1
Often overshadowed by more common genitourinary cancers, such as prostate, testicular, and kidney cancers, penile and urethral cancers nonetheless represent difficult treatment challenges for the clinician. The management 1
ESMO Clinical Practice Guidelines on Genitourinary Cancers: Prostate cancer, Bladder cancer, Renal cell cancer (RCC), Testicular seminoma...
Genitourinary cancers are comprised of physiologically complex and challenging-to-treat tumor types. In recent years, clinical and basic science research has resulted in many major advances in understanding the pathophysiology and management strategies of these diseases. In addition to the approval by the FDA of new pharmacological agents, the newly-gleaned insights and changing treatment strategies have led to the revision of current diagnosis and treatment guidelines.
Charles Drake, MD, PhD, discusses pairing immunotherapy with chemotherapy, the efficacy of current immunotherapy agents, and the future use of immunotherapy in the treatment of genitourinary cancers.
The upcoming 5th European Multidisciplinary Meeting on Urological Cancers (EMUC) is preceded by a special day-long ESU course on genitourinary cancer. The course is chaired by Profs. Palou and Van Poppel and features faculty from urological and oncological fields.. The ESU Medical Oncology course on Genitourinary Cancer (MOGUC) will take place on 14 November in Marseille, France, the day before the EMUC starts at the same venue. The course requires a separate registration, but a discount is available for people who attend both events. The MOGUC is accredited by the European Board of Urology within EU-ACME for 6 credits.. Prof. Hein Van Poppel, Executive Member of the EAU for Education and co-chair of the MOGUC explains the importance of the course for urologists: Urologists must realise that treatment goes beyond surgery. Much of the cancer treatment in Europe is done by medical oncologists, and urologists must be familiarised with new procedures and treatments. That way, they can better inform ...
SANTOS ARRONTES, D. et al. Genitourinary cancer incidence in a healt geographic area of 300.000 people. Actas Urol Esp [online]. 2004, vol.28, n.9, pp.646-649. ISSN 0210-4806.. OBJECTIVE: To provide descriptive information on site-specific urological cancer occurrence we computed 10-year cancer incidence rates in the geographic area of Getafe (Madrid, Spain, 300,000 people). MATERIALS AND METHODS: Only histologically confirmed genitourinary cancer (bladder, prostate, kidney, testicle and penis) throughout 1992-2001 was considered. Cancers were classified according to the international rules. 10 years age-standardized population-adjusted incidence rates per 100,000 people (or per 100,000 men when appropriate) were calculated. Overall and cancer-specific yearly increments were also evaluated. The most recent release of National Statistics (2001) was used for population adjusting. RESULTS: Prostate cancer (PC) accounted for the majority of diagnostics. A strong correlation was detected between the ...
TY - JOUR. T1 - Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma. AU - Huelsmann, Lorel. AU - Kim, D. Nathan W.. AU - Hannan, Raquibul. AU - Watumull, Lori M.. AU - Brugarolas, James. PY - 2015/8/1. Y1 - 2015/8/1. KW - Bone remodeling. KW - Everolimus. KW - Mammalian target of rapamycin (mTOR). KW - Osteoclasts. KW - Tuberous Sclerosis Complex 1 (TSC1). UR - http://www.scopus.com/inward/record.url?scp=84936985359&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84936985359&partnerID=8YFLogxK. U2 - 10.1016/j.clgc.2014.12.007. DO - 10.1016/j.clgc.2014.12.007. M3 - Article. C2 - 25620636. AN - SCOPUS:84936985359. VL - 13. SP - e321-e323. JO - Clinical Genitourinary Cancer. JF - Clinical Genitourinary Cancer. SN - 1558-7673. IS - 4. ER - ...
Dr. Kamran is a radiation oncologist at the Massachusetts General Hospital Cancer Center and Instructor at Harvard Medical School. In her clinic, she specializes in the treatment of genitourinary cancers. Her research interests focus on the application of computational genomic approaches to characterize tumor evolution to treatment and understand mechanisms of toxicity and resistance to radiation and chemoradiation. Her long-term goal is to use these approaches to guide the design of clinical trials of high-precision radiation therapy to enable personalized approaches to delivery of radiation therapy for patients with genitourinary cancers. Her research has received distinctions from the American Society for Radiation Oncology (Basic/Translational Science Research Award) as well as the MGH Department of Radiation Oncology William Shipley Research Award. Dr. Kamran was nationally recognized as a 40 Under 40 in Cancer Rising Stars and Emerging Leaders by the Lynx Group/McGivney Global Advisors ...
To make male hormone. Its been discovered that all men who develop testicular cancer are born with an abnormality on their 12th chromosome.. • There are two main types of testicular cancer - seminoma and non-seminoma - which develop from germ cells in the testicles. There are also different subtypes of testicular cancer.. • Treatment usually involves surgery to remove the testicle that has the cancer.. If you have testicular cancer, you may also need chemotherapy and/or radiation therapy. Both of these can be used to treat even advanced cases that have spread into other areas of the body. ...
Management of infusion reactions to systemic anticancer therapy • Management of toxicities from immunotherapy • Management of febrile neutropaenia • MASCC and ESMO consensus guidelines for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting • Treatment of dyspnoea in advanced cancer patients • Central venous access in oncology • Management of oral and gastrointestinal mucosal injury • Management of refractory symptoms at the end of life and the use of palliative sedation • Advanced care planning in palliative care • Bone health in cancer patients • Cancer, fertility and pregnancy • Management of chemotherapy extravasation • Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy • Management of cancer pain • Management of venous thromboembolism in cancer patients • Prevention of chemotherapy and radiotherapy-induced nausea • Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients • ...
Published: Jun 15th, 2012. The Department recently received approval to establish the University of Florida Prostate Disease Center (UFPDC). The UFPDC is an inter-disciplinary, statewide research and education center that facilitates the development of […]. ...
Radiation therapy is sometimes used to treat urinary system cancers, especially bladder and urethral cancer. Radiation therapy utilizes focused doses
Patrick Kenney, MD is a fellowship-trained urologic oncologist who cares for patients with genitourinary cancer (kidney, bladder, prostate, upper tract, testis, penis and urethra) at Smilow Cancer Hospital at Yale-New Haven. As a fellowship-trained urologic oncologist, Dr. Kenneys clinical practice is focused solely on cancer care. He performs robotic, laparoscopic and open cancer surgery. Dr. Kenneys main clinical interest is on organ and functional preservation whenever feasible, using techniques such as partial nephrectomy for kidney cancer, neobladder formation after radical cystectomy, and nerve-sparing radical prostatectomy. He has a specific interest in clinical trials with a focus on studying the integration of surgery and systemic therapy for locally advanced and metastatic genitourinary cancers. In his clinical practice, Dr. Kenney emphasizes the importance of the doctor-patient relationship. Dr. Kenney strongly believes in the importance of effective communication with patients, ...
Patrick Kenney, MD is a fellowship-trained urologic oncologist who cares for patients with genitourinary cancer (kidney, bladder, prostate, upper tract, testis, penis and urethra) at Smilow Cancer Hospital at Yale-New Haven. As a fellowship-trained urologic oncologist, Dr. Kenneys clinical practice is focused solely on cancer care. He performs robotic, laparoscopic and open cancer surgery. Dr. Kenneys main clinical interest is on organ and functional preservation whenever feasible, using techniques such as partial nephrectomy for kidney cancer, neobladder formation after radical cystectomy, and nerve-sparing radical prostatectomy. He has a specific interest in clinical trials with a focus on studying the integration of surgery and systemic therapy for locally advanced and metastatic genitourinary cancers. In his clinical practice, Dr. Kenney emphasizes the importance of the doctor-patient relationship. Dr. Kenney strongly believes in the importance of effective communication with patients, ...
Patrick Kenney, MD is a fellowship-trained urologic oncologist who cares for patients with genitourinary cancer (kidney, bladder, prostate, upper tract, testis, penis and urethra) at Smilow Cancer Hospital at Yale-New Haven. As a fellowship-trained urologic oncologist, Dr. Kenneys clinical practice is focused solely on cancer care. He performs robotic, laparoscopic and open cancer surgery. Dr. Kenneys main clinical interest is on organ and functional preservation whenever feasible, using techniques such as partial nephrectomy for kidney cancer, neobladder formation after radical cystectomy, and nerve-sparing radical prostatectomy. He has a specific interest in clinical trials with a focus on studying the integration of surgery and systemic therapy for locally advanced and metastatic genitourinary cancers. In his clinical practice, Dr. Kenney emphasizes the importance of the doctor-patient relationship. Dr. Kenney strongly believes in the importance of effective communication with patients, ...
TY - JOUR. T1 - Response of metastatic renal medullary carcinoma to carboplatinum and paclitaxel chemotherapy. AU - Gangireddy, Venu Gopala Reddy. AU - Liles, Georgia B.. AU - Sostre, Gilberto D.. AU - Coleman, Teresa. N1 - Copyright: Copyright 2012 Elsevier B.V., All rights reserved.. PY - 2012/6. Y1 - 2012/6. KW - Carboplatinum. KW - Hemoglobinopathies and renal cancer. KW - Paclitaxel. KW - Renal medullary carcinoma. KW - Sickle cell disease. UR - http://www.scopus.com/inward/record.url?scp=84862082383&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84862082383&partnerID=8YFLogxK. U2 - 10.1016/j.clgc.2012.01.003. DO - 10.1016/j.clgc.2012.01.003. M3 - Article. C2 - 22409864. AN - SCOPUS:84862082383. VL - 10. SP - 134. EP - 139. JO - Clinical Genitourinary Cancer. JF - Clinical Genitourinary Cancer. SN - 1558-7673. IS - 2. ER - ...
Prostate cancer is the most common male malignancy but its progression rate is only 30%. In autopsy series, it has been shown that it may be present in a greater percentage than usually estimated, from the 4th decade. More refined detection methods are increasing the number of patients undergoing radical surgical treatment for tumors that perhaps would not progress.. Due to the difficulties in obtaining samples for high throughput molecular analysis from early tumors, genes that could be decisive for the transition from a latent phase to an aggressive one leading to progression, are still unknown. Therefore, there are no clues to select patients for a less radical treatment. If genes distinguishing these groups were identified, a better knowledge of the natural history of prostate cancer could be gained, and it could be applied to better identifying patient risk and to designing more precise therapeutic strategies. ...
CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients.. Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions.. ...
Dr. Neeraj Agarwal, MD, a Profesor of medicine, is a physician and an investigator at the Huntsman Cancer Institute (HCI), University of Utah. At the HCI, he d
Copyright © 2020 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.. ...
New immunotherapy medications used for the treatment of kidney, bladder and prostate cancer include nivolumab, ipilimumab, pembrolizumab, avelumab.
Patterns of care will evolve following the COVID-19 pandemic. Telemedicine, virtual care, and telemonitoring will increase and could offer broader access to multidisciplinary expertise without increasing costs. Comprehensive and integrative telehealth solutions will be necessary, and should consider patients mental health and access differences due to socioeconomic status. Investigations and treatments will need to maximise efficiency and minimise health care interactions. Solutions such as one stop clinics, day case surgery, hypofractionated radiotherapy, and oral or less frequent drug dosing will be preferred. The pandemic necessitated a triage of those patients whose treatment should be expedited, delayed, or avoided, and may persist with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in circulation. Patients whose demographic characteristics are at the highest risk of complications from COVID-19 may re-evaluate the benefit of intervention for less aggressive cancers. Clinical ...
When caring for someone with urinary system cancer, you will need to:keep an eye on the persons symptoms;make sure they receive effective treatment;m
Search clinical trials and research studies at Indiana CTSI, IN. The most up-to-date database listing of new treatments being investigated at Indiana CTSI. Volunteer for Clinical Trials on ...Powered by iConnect Clinical Trials Finder and Patient Recruitment Tool.
CME credits:1.0 AMA/PRA Category 1 Credit™ The City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. City of Hope designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.TM. ...
The median progression-free survival to taxane therapy was comparable in AR-V7-positive and AR-V7-bad men . The AR-V7 abnormality takes place more often among
Genitourinary Cancer / Urologic Oncology Tumor Board (Non-CME)A multidisciplinary panel of physician-scientists that specialize in cancers of the genitourinary tract meets weekly to review new patients cases for prostate, kidney, bladder, testis and other complex GU cancers. The main clinical disciplines represented include faculty from urology, medical oncology, radiation oncology, pathology and radiology.The group will evaluate the patients medical history and recent diagnostic testing/scans, collaborating to recommend a strategic treatment plan that best utilizes the array of clinical resources available at Weill Cornell Medicine / NewYork-Presbyterian Hospital.Tumor Board meets on every Monday at 4:00PM in in the Pathology Conference room at NYP-WCM: 525 East 68th Street, 10th floor of the Starr Pavilion, Room Starr-1006.This meeting is open to physicians outside of WCM-NYP to present a patients case for discussion. In order to present, you must bring pathology and imaging for the patient that
Terms Breast cancer Cancer that starts in the cells of the breast tissues, most commonly in the ducts and lobules. Endocrine cancer Cancer that starts in the hormone-producing glands of the body, such as the thyroid, parathyroid, pituitary, pancreas, and adrenal glands, and gut. Gastrointestinal cancer Cancer that starts in the esophagus, stomach, bowel and rectum, liver or pancreas. Genitourinary cancer Cancer that affects the genitourinary tract, such as the kidney, bladder, prostate, or testis.
TY - JOUR. T1 - Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. T2 - Clinical Genitourinary Cancer. AU - Rosiello, G.. AU - Knipper, S.. AU - Palumbo, C.. AU - Pecoraro, A.. AU - Luzzago, S.. AU - Deuker, M.. AU - Tian, Z.. AU - Gandaglia, G.. AU - Gallina, A.. AU - Montorsi, F.. AU - Shariat, S.F.. AU - Saad, F.. AU - Briganti, A.. AU - Karakiewicz, P.I.. N1 - Cited By :1 Export Date: 11 March 2021 Correspondence Address: Rosiello, G.; Department of Urology and Division of Experimental Oncology, Via Olgettina, Italy; email: [email protected] PY - 2020. Y1 - 2020. N2 - Background: Our objective was to test whether the rates of perioperative chemotherapy (CHT) administration in patients with urothelial bladder cancer (UCUB) with prostatic stromal invasion (pT4a) changed over time. Moreover, we tested the effect of CHT on overall mortality (OM), as well as on cancer-specific ...
Acute Lymphoblastic Leukemia Treatment Acute Myeloid Leukemia Treatment Anal Cancer Treatment Basal Cell Carcinoma Treatment Bladder Cancer Treatment Bone & Spine Sarcoma Treatment Bone Cancer Treatment Brain Cancer Treatment Breast Cancer Treatment Cervical Cancer Treatment Chronic Lymphocytic Leukemia Treatment Chronic Myeloid Leukemia Treatment Colon Cancer Treatment Cranial Base Center Treatment Cutaneous Lymphoma Treatment Endocrine Cancers Treatment Endometrial Cancer Treatment Esophageal Cancer Treatment Gallbladder Cancer Treatment Gastrointestinal Cancers Treatment Gastrointestinal Carcinoid Tumors Treatment Genitourinary Cancers Treatment Gliomas Treatment Gynecologic Cancers Treatment Hairy Cell Leukemia Treatment Head & Neck Cancers Treatment Hemophilia Treatment Hodgkins Lymphoma Treatment Kaposi Sarcoma Treatment Kidney Cancer Treatment Laryngeal Cancer Treatment Leukemia Treatment Lip & Oral Cavity Cancer Treatment Liver Cancer Treatment Lung Cancers Treatment Lymphoma Treatment ...
At the 2017 Genitourinary Cancers Symposium, Nicholas J. Vogelzang, MD, discussed diagnostic practices and emerging therapies in the field of bladder cancer.
SAN FRANCISCO-The length of time from nephrectomy up until the diagnosis of metastatis has been confirmed as prognostic for patients whose renal cell carcinoma was treated with targeted therapies - just as it is in patients overall - according to a retrospective analysis reported to the ASCO Genitourinary Symposium by Professor Giuseppe Procopio, who is a clinical researcher specializing in medical therapies for genitourinary cancers at the Istituto Nazionale dei Tumori in Milan. In his presentation, however, he highlighted the need for randomized controlled studies to determine the effects of nephrectomy on the disease process. He explained that currently it is unclear whether surgery is causative of a good outlook or whether patients whose metastases emerged later have more benign disease than those whose disease becomes metastatic sooner.. CONTACT ...
McGowan, D, Hunt, D, Jones, C, et al. Effect of short-term endocrine therapy prior to and during radiation therapy on overall survival in patients with T1b-T2b adenocarcinoma of the prostate and PSA equal to or less than 20: Initial results of RTOG 94-08 (abstract). American Society of Clinical Oncology (ASCO) 2010 Genitourinary Cancers Symposium. (Abstract available online: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_meeting_categories_view&confID=73, accessed on March 19, 2010 ...
This week sees the start of the American Society of Clinical Oncology Symposium on Genitourinary Cancers (ASCO GU) in San Francisco.. Prostate cancer has certainly been in the minds of investors the past few weeks in anticipation of the COMET-1 prostate cancer trial results for cabozantinib (Cometriq).. The share price went on a run-up until Exelixis CEO Michael Morrissey took yet another trip to the biotech ATM machine. Somehow, this doesnt come as any surprise given past performance. The key issue at stake here, however, is will the COMET-1 trial be positive or negative? The outcome is much anticipated and will no doubt influence the chances of successful approval for cabozantinib in advanced prostate cancer. Data is expected sometime in first half of this year.. What we can expect in the media this week is more news on the Medivation and Astellas phase 3 trial PREVAIL clinical trial of enzalutamide (Xtandi) in men with advanced prostate cancer who had not yet received chemotherapy. The ASCO ...
1 http://www.auanet.org/education/guidelines/prostate-cancer.cfm. 2 Basch E, Autio K, Ryan CJ, et al: Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. The Lancet Oncology. 2013; 14(12):1193-1199.. 3 Beer TM, Armstrong AJ, Sternberg CN, et al: Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study. Presented at the 2014 Genitourinary Cancers Symposium. Journal of Clinical Oncology. 2014; 32 (supplement 4; abstract LBA1).. 4 Nelson J, Banato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer2003;3(2):110-116.. 5 Scher HI, Fizazi K, Saad F et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Eng J Med 2012; 367: 1187.. 6 de Bono JS, Logothetis CJ, Molina A et al: Abiraterone and increased survival in metastatic prostate ...
Ahead of a planned launch of its prostate cancer prognostic test, Decipher, later this year, GenomeDx presented data from four studies at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium last week.
Experts in testicular cancer treatment and diagnosis, Scripps MD Anderson offers a patient-first approach to treating genitourinary cancers in San Diego.
Hoffman, H. T., Walvekar, R. R., Tracy, C. R., Kolenda, J. & Pagedar, N. (2016). Endoscopic Salivary Stone Fragmentation with Pneumatic Lithotripsy in a Simulation Model. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 154(3), 454-9. PMID: 26786265.. Watkins, J. M., Mitchell, D. L., Russo, J. K., Mott, S. L., Tracy, C. R., Smith, M. C. & Buatti, J. M. (2016). Gleason Score = 6 Prostate Cancer at Radical Prostatectomy: Does a High-Risk Setting Truly Exist? A Recursive Partitioning Analysis. Clinical genitourinary cancer. PMID: 27338519.. Moriarty, M. A., Nepple, K. G., Tracy, C. R., Strigenz, M. E., Lee, D. K. & Brown, J. A. (2016). Impact of Robotic Fellowship Experience on Perioperative Outcomes of Robotic-Assisted Laparoscopic Partial Nephrectomy. Current urology, 9(1), 19-23. PMID: 26989366.. Mitchell, D. L., Tracy, C. R., Buatti, J. M., Smith, M. C., Snow, A. N., Henry, M. D., Vaena, D. A., Tewfik, H. H. & Watkins, J. M. ...
Journal of Oncology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to breast cancer, lung cancer, gastrointestinal cancer, skin cancer, head and neck cancer, paediatric oncology, neurooncology as well as genitourinary cancer. The journal provides a multidisciplinary forum for translational and clinical oncology research in the areas of molecular pathology, genomics, diagnosis and therapy, with a specific focus on molecular targeted agents and novel immune therapies.
Journal of Oncology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to breast cancer, lung cancer, gastrointestinal cancer, skin cancer, head and neck cancer, paediatric oncology, neurooncology as well as genitourinary cancer. The journal provides a multidisciplinary forum for translational and clinical oncology research in the areas of molecular pathology, genomics, diagnosis and therapy, with a specific focus on molecular targeted agents and novel immune therapies.
Cabozantinib achieved superior progression-free survival (PFS) versus standard treatment with everolimus in patients with previously treated advanced kidney cancer in an updated analysis of the phase 3 METEOR trial reported at the Genitourinary Cancers Symposium. In addition, a strong trend toward overall survival (OS) favored cabozantinib at an interim analysis, showing a 33% improvement versus everolimus.. Final OS results will be presented at ASCO in June.. Current treatments can provide some benefit to patients with advanced kidney cancer, but we need treatments that are more effective and can overcome treatment resistance. Our preliminary results suggest that cabozantinib may help overcome treatment resistance and provide new hope to patients with this aggressive cancer, said lead author Bernard Escudier, MD, Institut Gustave Roussy, Villejuif, France.. Cabozantinib targets MET and AXL, which are associated with poor prognosis and resistance to tyrosine kinase inhibitors (TKIs), he ...
The Urology Department was started in 1979 and was the first Urology Department to be established in any institution covered under the Central Health Service. Subsequently a M.Ch. (Urology) Super Speciality Degree Course was started in 1987. This was the first Super Speciality Degree Course started at JIPMER, Pondicherry and the first Urology Super Speciality Course to be established in any institution covered under the Central Health Service. The services provided by the department include paediatric endoscopy, urodynamics, image guided urological interventions, upper and lower urinary tract endourology, extracorporeal shock wave lithotripsy for renal stone treatment, reconstructive urology, treatment of urinary incontinence, treatment for sexual dysfunction and infertility in male, urological laparoscopy, genitourinary cancer surgery and renal transplant surgery was started in March 2012. Further strides in the field of renal transplantation were made with the start of laparoscopic live donor ...
Following faculty appointments at the University of Utah and the University of Cincinnati, he has spent the last five years as professor of pediatrics and chief of the Division of Pediatric Hematology/Oncology, and Childrens Miracle Network Research Chair in Pediatrics at the University of Kentucky. Her clinical and research interests are focused on the treatment of lung cancer, genitourinary cancers, high dose IL2 and early phase clinical trials of new. Contact Information. Coutts is a board certified oncology pharmacist who has been with TriHealth since graduating from the University of Cincinnati in 2004. - RAPID RUN were also likely to be searching for these additional terms. It is the principal institution dedicated exclusively to medical services to the children in Puerto Rico and the Caribbean. Find researchers and browse publications, full-texts, contact details and general information related to the Division of Hematology Oncology at University of Cincinnati. ) degree from the ...
Groin dissection is an important part of surgical treatment of cutaneous and genitourinary cancer leading to accurate and regional control of the disease [16]. However, it is well known that prolonged wound drainage and seroma formation occurs in a significant number of patients delaying their postoperative recovery and affecting the quality of life adversely. There was recently quite enthusiasm to use fibrin tissue sealant over the raw area following lymphadenectomy to reduce the wound drainage. However, our study reveals that it is neither helpful in reducing the wound drainage nor the number of clinically evident seromas. In a recently conducted meta-analysis of six Randomized Controlled Trials (RCTs), Weldrick C et al concluded that Tissue fibrin sealant does not significantly reduce Surgical Site Infection (SSI) or number of seromas in patients undergoing groin dissection with tissue Fibrin Sealant (FS) compared to Standard Closure (SC) techniques. The overall incidence of SSI in the FS ...
Myopia is a public health problem in the world and its prevalence and incidence are rising in recent years. Studies have shown that myopia is a kind of complex genetic diseases. And sclera-remodeling plays an important role in the development of myopia. The recent research advances in association with both sclera-remodeling relevant gene polymorphisms and myopia are reviewed in this article. (Chin J Ophthalmol, 2016, 52: 876-880).
Toxoplasma gondii microneme proteins (TgMICs), secreted by micronemes upon contact with host cells, are reported to play important roles in multiple stages of the T. gondii life cycle, including parasite motility, invasion, intracellular survival, and egress from host cells. Meanwhile, during these processes, TgMICs participate in many protein-protein and protein-carbohydrate interactions, such as undergoing proteolytic maturation, binding to aldolase, engaging the host cell receptors and forming the moving junction (MJ), relying on different types of ectodomains, transmembrane (TM) domains and cytoplasmic domains (CDs). In this review, we summarize the research advances in protein-protein and protein-carbohydrate interactions related to TgMICs, and their intimate associations with corresponding biological processes during T. gondii infection, which will contribute to an improved understanding of the molecular pathogenesis of T. gondii infection, and provide a basis for developing effective ...
I am a urologic surgeon with expertise in the management of genitourinary malignancies and a special interest in using robotic and minimally invasive surgery to treat cancers of the kidney, prostate, bladder and adrenal glands. My goal is to educate and empower my patients so that they can choose the best treatment option available, whether it is surgery, active surveillance, radiation, systemic therapy, or a clinical trial. To that end, I work closely with my Medical Oncology and Radiation Oncology colleagues in order to offer patients an effective, individualized, and comprehensive cancer treatment plan that minimizes side effects and maximizes quality-of-life. I joined the faculty of the Cancer Institute of New Jersey in 2012 after completing a clinical and research fellowship in the Urologic Oncology Branch of the National Cancer Institute (NCI). I received my medical degree (MD) with Honors in Research from Georgetown University along with a masters degree (MA) in bioethics. I performed my ...
Objective: We aimed to evaluate the efficacy of the percutaneous nephrostomy (PN) performed by using combined ultrasonography (USG) and fluoroscopy. Methods: Eighty-seven patients (48 female, 39 male; mean age, 58.2; range, 19-91) who underwent 106 PN procedures performed by using USG and fluoroscopy combination between July 2011 and May 2015 were retrospectively analyzed. The technical success was considered if nephrostomy catheter was placed within renal pelvis and functioned spontaneously. All patients received preprocedural prophylactic antibiotic and preprocedural coagulation parameters and platelet count were tested in all patients routinely. The procedural complications are classified as major, minor and catheter-related. The technical success rates and complication rates of the PN procedure were calculated. Results: PN was performed for benign causes in 47 patients (54%) and for malignant causes in 40 patients (46%). A total of 106 nephrostomies were performed in 101 kidneys (95.1%) with dilated
For upper respiratory tract infections due to streptococci, pneumococci, non-penicillinase-producing staphylococci and H, influenzae) or Genito-Urinary Tract Infections (due to Escherichia coli. Proteus mirabilis and Streptococcus faecalis or Skin and Soft Tissue Infections due to streptococci, sensitive staphylococci and Escherichia coli. Adults: 250 mg every 8 hours.. For lower respiratory tract infections (due to streptococci, pneumococci, non-penicillinase producing staphylococci and H, influenzae. Adults: 500 mg every 8 hours.. Other infections, consult doctors for its corresponding dosage. Please see label. For more detailed information please consult specialist. Do not take more of Amoxicillin Cap than it is indicated at the label without consulting your doctor. ...
Buy Biomoxil Online! Biomoxil should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. Biomoxil is indicated for the short term treatment of common bacterial infections in adults and children such as: Upper Respiratory Tract Infections (including ENT): e.g. tonsillitis, sinusitis, otitis media; Lower Respiratory Tract Infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia; Genito-urinary Tract Infections: e.g. cystitis
Buy Biomoxil Online! Biomoxil should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. Biomoxil is indicated for the short term treatment of common bacterial infections in adults and children such as: Upper Respiratory Tract Infections (including ENT): e.g. tonsillitis, sinusitis, otitis media; Lower Respiratory Tract Infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia; Genito-urinary Tract Infections: e.g. cystitis
Buy Ranclav Online! Ranclav should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. Ranclav is indicated for the short term treatment of common bacterial infections in adults and children such as: Upper Respiratory Tract Infections (including ENT): e.g. tonsillitis, sinusitis, otitis media; Lower Respiratory Tract Infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia; Genito-urinary Tract Infections: e.g. cystitis, u
Buy Bactoclav Online! Bactoclav should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. Bactoclav is indicated for the short term treatment of common bacterial infections in adults and children such as: Upper Respiratory Tract Infections (including ENT): e.g. tonsillitis, sinusitis, otitis media; Lower Respiratory Tract Infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia; Genito-urinary Tract Infections: e.g. cysti
Buy Duomox Online! Duomox should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. Duomox is indicated for the short term treatment of common bacterial infections in adults and children such as: Upper Respiratory Tract Infections (including ENT): e.g. tonsillitis, sinusitis, otitis media; Lower Respiratory Tract Infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia; Genito-urinary Tract Infections: e.g. cystitis, uret
Buy Promox Online! Promox should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. Promox is indicated for the short term treatment of common bacterial infections in adults and children such as: Upper Respiratory Tract Infections (including ENT): e.g. tonsillitis, sinusitis, otitis media; Lower Respiratory Tract Infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia; Genito-urinary Tract Infections: e.g. cystitis, uret
Secretory Immunoglobulin A (SIgA) is a subclass of Immunoglobulin A (IgA), an antibody that plays a critical role in mucosal immunity. SIgA is the main immunoglobulin found in mucous secretions from tear glands, salivary glands, mammary glands, the respiratory system, the genito-urinary tract, and the gastrointestinal tract. (1) SIgA is not synthesized by mucosal epithelial cells in these structures or derived from blood. Instead, it is produced by B-lymphocytes adjacent to the mucosal cells, then transported through the cell interiors, and released into the secretions from the cells. (2) SIgA plays a key role in protecting vulnerable areas such as the oral cavity, lungs, and gut from invading pathogens. (1) Differences in SIgA levels in the saliva from different glands have been observed in humans, with the highest levels found in the minor saliva glands. (2,3) SIgA exhibits a diurnal rhythm, decreasing from the highest levels in the morning to the lowest in the evening. (4) Read More... ...
27 scientific presentations, including long-term data from Calquence in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic leukaemia. New data on six medicines and potential new medicines across a variety of blood cancers demonstrate breadth of haematology portfolio. AstraZeneca, together with Acerta Pharma, its haematology research and development centre of excellence, and MedImmune, its global biologics research and development arm, will present 27 abstracts, including six oral presentations, at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, USA, December 1-4.. New data include presentations on Calquence (acalabrutinib) and Lumoxiti (moxetumomab pasudotox-tdfk), as well as research findings from AstraZenecas early pipeline across a variety of blood cancers.. Dave Fredrickson, Executive Vice President, Head of Oncology Business Unit, said: In less than a year, we have launched two innovative medicines to treat blood ...
New medicines to fight heart disease, updated guidelines for strokes and high blood pressure, and research into genome editing are among the top heart disease and stroke advances in 2017, according to the American Heart Association, the worlds leading voluntary health organization devoted to fighting cardiovascular disease and stroke.
Advances in presbyopia, dry eye and allergy, and age-related macular degeneration filled this years meeting of the Association for Research in Vision and Ophthalmology.
Message from the DirectorThe National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
Abstract: Because of their high energy density and long cycle life, lithium-ion batteries (LIBs) have dominated the portable electronics market for over 20 years. However, with the increasing demand for large-scale energy storage systems for grid applications, the price of Li resources has increased owing to the low abundance of Li in Earths crust and non-uniform distribution on the planet. Because Na has similar physical and chemical properties as Li and is an abundant natural resource, room-temperature sodium-ion batteries (SIBs) are expected to be among the most promising next-generation large grid energy storage devices. It is known that the cathode, anode, separator and electrolyte materials are the main components of batteries. Among these, Na-containing cathode materials are of critical importance. As a cathode material for SIBs, polyanion-type compounds have become a hot research topic owing to their versatile structural frameworks, high thermal stabilities, high ambient stabilities ...
(PhysOrg.com) -- A comparison of methane emissions from three ruminant species eating different forages, with and without feed additives, found chicory will reduce methane emissions in sheep - but also highlighted the challenges in identifying mitigation strategies and shown the need for further research.
Twenty years after stem cell research seemed poised to change the world with the possibility of curing a wide range of diseases, and then struggled in fits and startsamidscientific and political obstacles, it isclearly morphing into new areas.
Thalidomide - Learn about the history, research, side effects and uses, including multiple myeloma treatment, of thalidomide and related drugs.
Medical Xpress is a web-based medical and health news service that features the most comprehensive coverage in the fields of neuroscience, cardiology, cancer, HIV/AIDS, psychology, psychiatry, dentistry, genetics, diseases and conditions, medications and more. ( ... sorted: liverank/1m)(... continued page 3)
When I woke up automatically at 2:30 am this morning, I wasnt surprised. The Nobel Prize in Physiology or Medicine was scheduled to be announced at that time
Ive received a few emails recently asking me what I ate during my two-week wait after our embryo transfer. And even though my embryo transfer ended in October, I remember the wait like it was yesterday! And if youve been reading the blog long enough, you already know I could not even wait the entire two weeks (it was
If you are going through the two-week wait or preparing for IVF/egg donation in the nearest future, this webinar is everything you are looking for.
We observed an increased risk of prostate cancer in association with coumaphos exposure among men with a family history of prostate cancer but not among men without a family history in both early (1993-1999) and later periods in cohort follow-up (2000-2005), although the interaction rate ratio in the early period is stronger than in the later period ...
Our lab is interested in elucidating genetic mechanisms that control the generation of brain complexity and the formation of brain tumors. The increased brain complexity is believed to be responsible for higher intellectual ability in humans. Generating brain complexity requires the maintenance of neural stem cells (NSCs) and the production of intermediate neural progenitor cells (INPs), transient amplification of which is critical for boosting the number of neurons and glia generated from NSCs. However, aberrant proliferation of NSCs and INPs can lead to brain tumor formation. In our lab, we use a particular type of NSCs called type II neuroblasts (NBs) in Drosophila larval brains as a model to dissect genetic mechanisms that control the maintenance of NSCs and the generation of INPs. Drosophila type II NBs remarkably resemble mammalian NSCs. They can not only maintain their own population through self-renewal throughout the larval development but also produce large amount of neurons by ...
A major £2.4 million research project is underway at the University of Birmingham aimed at improving treatment for women with polycystic ovary syndrome.
Upstate boasts basic and clinical researchers with diverse expertise in neuroscience, molecular genetics, genomics, epigenetics, structural biology, infectious disease, and behavior disorders. This allows students the opportunity to perform research in a wide range of research areas and easily collaborate when new expertise is needed. ...
Story posted June 27, 2002. Bruce D. Kohorn, professor of biology and biochemistry at Bowdoin College, has been awarded a National Science Foundation grant totaling $289,089 for the purchase of a confocal laser scanning microscope. The grant is funded through the NSFs Major Research Instrumentation Program.. The microscope, which has been purchased and will arrive in the fall, will be the only such instrument in Maine at a liberal arts undergraduate institution.. Were very excited to be able to acquire a confocal laser scanning microscope at Bowdoin, said Kohorn. Students using the instrument in research labs will be exposed to current and standard technologies theyll need for more advanced degree programs. This work will prepare them for careers in biology and related fields by providing the technical and theoretical background for one of the most common methods of imaging in cell and molecular biology.. The instrument will also be used in major research projects by Bowdoin ...
The FY 2002 Budget Request includes $16.90 million for construction of two detectors of the Large Hadron Collider (LHC). These are ATLAS (A Toroidal Large Angle Spectrometer) and CMS (Compact Muon Solenoid). To complete the project, this budget requests advance appropriations of $9.70 million in FY 2003. Total NSF funding for this project is $81.0 million over the period FY 1999-2003. Oversight of this project is provided through the Physics Subactivity within the Mathematical and Physical Sciences (MPS) Activity.. The LHC is being constructed at the CERN laboratory in Switzerland. The facility will consist of a superconducting particle accelerator providing two counter-rotating beams of protons, each with energies up to 7 TeV (7x1012 electron volts). ATLAS and CMS are being constructed to characterize the reaction products produced in the very high energy proton-proton collisions which will occur at intersection regions where the two beams collide. The LHC will enable a search for the Higgs ...
Widener is an innovative metropolitan university offering undergraduate and graduate programs that combine academic excellence, career preparation and community service.
Testicular Cancer - In most cases, male patients have their testicles examined by a physician during a regular physical exam. However, men should keep an eye out for anything unusual about their testicles.Symptoms of testicular cancer include lumps, swelling, enlargement, ache in the groin area, and fluid in the scrotum to name a few. If testicular cancer has been detected, the most common treatment options include surgery to remove one or both testicles and radiation therapy.Prostate Cancer - Prostate is the most commonly diagnosed urologic cancer in men, but it also has one of the best survival rates at 97 percent. Common symptoms of prostate cancer include frequent urination and a strong, sudden urge to urinate.. An interrupted or weak urine stream may also be a sign of prostate cancer, as is painful burning while urinating. Treatment options include active surveillance, chemotherapy, and surgery to remove the cancerous part of the prostate.. Bladder Cancer - Bladder cancer is another common ...
USMD urology doctors know a prostate cancer or urologic cancer diagnosis is scary. They also know each patients treatment journey is different. Thats why USMD offers a wide range of world-class options for treating prostate, kidney, bladder, testicular and penile cancer. With USMD, you get personalized care for your specific needs.
Discover our focus and learn more about our innovative treatment methods in the area of urological cancers. Call (888) 264-1533 today to schedule an appointment with our specialists.
This delay in diagnosis is often the bane of lung cancer patients and costs them dearly, says Dr Surya Kant, Head of the Pulmonary Medicine Department at KGMU, and Vice-President of Indian Chest Society. Diagnosis of lung cancer is very difficult and often delayed as its symptoms closely mimic those of TB. In our country two third cases of lung cancer are misdiagnosed as TB at the first go. So by the time patients come to our hospital, they have already wasted at least 6 months on unnecessary TB treatment, during which time the cancer advances from its operable to non operable stage. If Ismail had been diagnosed 6 months earlier in the operable stage of his cancer, he had better survival chances. But in our country only 10% patients are diagnosed in the operable 1st and 2nd stages of lung cancer. Timely surgery results in 5 years survival in 50% of the patients ...
At MedStar Washington, we provide comprehensive diagnosis and treatment of urologic cancer. Request an appointment in DC or Maryland today.
Psycho-oncologic support could help patient with urologic cancer manage the effects of emotional stressors related to their diagnosis.
There was an extra six cases per one thousand who had been diagnosed with cancer, which is a significant figure. As the function of the kidney deteriorated, the risk became the same as those requiring new kidneys or regular time on a dialysis machine.. Over twenty per cent of men will suffer from a chronic form of kidney disease which put makes these findings very important. As well as cancer of the lung there are also at risk from urinary cancer too.. Wong continues that neither, prostate or colorectal cancer, were connected to these conditions. She believes that public awareness is the key, as the main causes of kidney disease in America are high blood pressure and diabetes, with men being notorious for not seeking medical attention.. Ultimately making the early symptoms known to the wider population can make a real difference and even save hundreds of lives each year.. ...
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials